期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

N-乙酰半胱氨酸预防造影剂肾病的作用 被引量：5

暂未订购
导出
摘要 目的探讨双倍剂量的N-乙酰半胱氨酸对冠心病并发糖尿病患者发生造影剂肾病的预防保护作用。方法选取行冠状动脉造影或介入治疗且并发糖尿病患者125例,随机分为A、B两组。两组在造影前后12 h给予0.9%氯化钠注射液水化治疗+N-乙酰半胱氨酸泡腾片,A组N-乙酰半胱氨酸泡腾片剂量为600 mg,bid,B组N-乙酰半胱氨酸泡腾片剂量为1 200 mg,bid,两组N-乙酰半胱氨酸泡腾片在造影前1 d和造影后48 h使用。比较造影前、造影后48 h血肌酐(SCr)、尿素氮(BUN)、肌酐清除率(CCr)、尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)、尿β2-微球蛋白(β2-MG)及造影剂肾病发生率等。结果 A、B两组在造影后48 h较造影前SCr、BUN、尿NAG及尿β2-MG都升高,CCr降低,差异无统计学意义(P>0.05)。与A组比较,B组造影后SCr、BUN、尿NAG及尿β2-MG都降低,CCr稍升高,差异无统计学意义(P>0.05)。B组造影剂肾病发生率(4.8%)明显低于A组(15.9%),差异有统计学意义(P<0.05)。结论双倍剂量的N-乙酰半胱氨酸比普通剂量的N-乙酰半胱氨酸对造影剂肾病有较好的预防保护作用。
作者 李飞 杨定平 贾汝汉 丁国华
机构地区 武汉大学人民医院肾内科
出处 《医药导报》 CAS 北大核心 2012年第4期452-454,共3页 Herald of Medicine
关键词 N-乙酰半胱氨酸 双倍剂量 肾病 造影剂
分类号 R981.1 [医药卫生—药品] R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献14

  • 1TEREZA P,GEORGE D,ROXANA M. Contrast-induced nephropathy[J].Catheterization and Cardiovascular Interventions,2008,(01):62-72.doi:10.1002/ccd.21207.
  • 2RIHAL C S,TEXTOR S C,GRILL D E. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention[J].Circulation,2002,(19):2259-2264.
  • 3SAFIRSTEIN R,ANDRADE L,VIEIRA J M. Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug[J].New England Journal of Medicine,2000,(03):210-212.
  • 4CAVUSOGLU E,CHHABRA S,MARMUR J D. The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention[J].Minerva Cardioangiologica,2004,(05):419-432.
  • 5CHERTOW G M,CHRISTIANSEN C L,CLEARY D P. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis[J].Archives of Internal Medicine,1995,(14):1505-1511.
  • 6GRUBERG L,MEHRAN R,DANGAS G. Acute renal failurerequiring dialysis after percutaneous coronary interventions[J].Catheterization and Cardiovascular Interventions,2001,(04):409-416.
  • 7HAEUSSLER U,RIEDEI M,KELLER F. Free reactive oxygen species and nephrotoxicity of contrast agents[J].Kidney and Blood Pressure Research,2004,(03):167-171.
  • 8THOMSEN H S. Guidelines for contrast media from the European Society of Urogenital Radiology[J].American Journal of Roentgenology,2003,(06):1463-1471.
  • 9FUNG J W,SZETO C C,CHAN W W. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency:a randomized trial[J].American Journal of Kidney Diseases,2004,(05):801-808.
  • 10TEPEL M,VANDER GIET M,SCHWARZFELD C. Prevention of radiographic-contrast-agent-induced reductions in renal fuction by acetylcysteine[J].New England Journal of Medicine,2000,(03):180-184.

同被引文献49

  • 1McCullough PA. Contrast-induced acute kidney in-jury[J]. J Am Coll Cardiol,2008,51(15) : 1419 —1428.
  • 2Patti G,Nusca A, Chello M, et al. Usefulness ofstatin pretreatment to prevent contrast-induced ne-phropathy and to improve long-term outcome in pa-tients undergoing percutaneous coronary interven-tion[J]. Am J Cardiol, 2008, 101(3) : 279 — 285.
  • 3Thomsen HS. Guidelines for contrast media fromthe European Society of Urogenital Radiology[J].AJR Am J Roentgenol 2003,181 ( 6 ) : 1463 —1471.
  • 4Rihal CS, Textor SC, Grill DE,et al. Incidenceand prognostic importance of acute renal failure af-ter percutaneous coronary iatervention[J]. Circula-tion, 2002,105(19): 2259-2264.
  • 5Pannu N, Wiebe N, Tonelli M. Prophylaxis strate-gies for contrast-induced nephropathy [J]. JAMA,2006,295(23) : 2765 - 2779.
  • 6Marenzi G,Lauri G,Assanelli E,et al. Contrast-induced nephropathy in patients undergoing primaryangioplasty for acute myocardial infarction [J ]. JAm Coll Cardiol, 2004, 44(9): 1780 — 1785.
  • 7Schweiger MJ, Chambers CE,Davidson CJ,et al.Prevention of contrast induced nephropathy j recom-mendations for the high risk patient undergoing car-diovascular procedures[J]. Catheter Cardiovasc In-terv, 2007,69(1): 135 — 140.
  • 8Chello M, Goffredo C, Patti G, et al. Effects ofatorvastatin on arterial endothelial function in coro-nary bypass surgery[J]. Eur J Cardiothorac Surg,2005’ 28(6): 805-810.
  • 9Loboda A,Jazwa A,Jozkowicz A,et al. Atorvas-tatin prevents hypoxia-induced inhibition of endo-thelial nitric oxide synthase expression but does notaffect heme oxygenase-1 in human microvascularendothelial cells [J]. Atherosclerosis, 2006,187(1): 26-30.
  • 10Shepherd J, Kastelein JJ,Bittner V,et al. Effect ofintensive lipid lowering with atorvastatin on renalfunction in patients with coronary heart disease: theTreating to New Targets (TNT) study[J]. Clin JAm Soc Nephrol,2007,2(6) ; 1131 —1139.

引证文献5

二级引证文献26

医药导报
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部